FIGURE 41. Empirical and modelled OS for nilotinib and imatinib in the corrected version of Novartis's AP model.

FIGURE 41Empirical and modelled OS for nilotinib and imatinib in the corrected version of Novartis's AP model

From: 6, Cost-effectiveness: chronic myeloid leukaemia in accelerated phase

Cover of Dasatinib and Nilotinib for Imatinib-Resistant or -Intolerant Chronic Myeloid Leukaemia: A Systematic Review and Economic Evaluation
Dasatinib and Nilotinib for Imatinib-Resistant or -Intolerant Chronic Myeloid Leukaemia: A Systematic Review and Economic Evaluation.
Health Technology Assessment, No. 16.22.
Rogers G, Hoyle M, Thompson Coon J, et al.
Southampton (UK): NIHR Journals Library; 2012 Apr.
© 2012, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.